Profile of etravirine for the treatment of HIV infection - Wikidata - awgldk - TriplyDB

Profile of etravirine for the treatment of HIV infection

Profile of etravirine for the treatment of HIV infection

http://www.wikidata.org/entity/Q33635039

about

Pharmacokinetics of Once-Daily Darunavir/Ritonavir With and Without Etravirine in Human Immunodeficiency Virus-Infected Children, Adolescents, and Young Adults.Artemether-Lumefantrine Combination Therapy for Treatment of Uncomplicated Malaria: The Potential for Complex Interactions with Antiretroviral Drugs in HIV-Infected Individuals.

P2860

Q33609231-98770B8B-1E6B-49B9-B734-2578FF982FBC Q35692270-263C1ABD-407B-4B23-A3B2-70DEE5278F6C

P2860

Profile of etravirine for the treatment of HIV infection

http://www.wikidata.org/entity/Q33635039

description

2010 nî lūn-bûn

@nan

2010 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Profile of etravirine for the treatment of HIV infection

@ast

Profile of etravirine for the treatment of HIV infection

@en

type

label

Profile of etravirine for the treatment of HIV infection

@ast

Profile of etravirine for the treatment of HIV infection

@en

prefLabel

Profile of etravirine for the treatment of HIV infection

@ast

Profile of etravirine for the treatment of HIV infection

@en

P1433

Q33635039-BB48D6B8-5BB2-4BA9-B768-7F8F9FD8A9BF

P1476

Q33635039-109C8827-45E4-409B-9BAD-B240DBFFD174

P2093

Q33635039-0D15F84A-164D-4B95-8908-4B66C60202F7

Q33635039-933BE930-DD68-48AC-97C1-6D3788111602

P2860

Q33635039-05885D7A-2AC1-4B2C-B5E0-A1AF5E123DB2

Q33635039-1582AEF5-CB13-41D2-85F2-95A3B9882C28

Q33635039-1BB3C179-D2EF-47D6-91AE-6103CCDDAE0C

Q33635039-1DA961F1-6FAF-4D78-9D6C-A9D3B7CBD5C7

Q33635039-30F2234E-BED5-4729-914A-05D0703ED385

Q33635039-4192D99D-BB6C-4401-9F50-745F03051EF3

Q33635039-47F23717-8DDE-47A6-898A-1CF4E0547DA2

Q33635039-54DCF00B-F8C6-4608-9255-2E4C94148029

Q33635039-5E88A542-ED67-4950-A8B5-BC75B5526E20

Q33635039-6047A99D-DCE2-43A0-A850-4BB73A4FAFB0

P304

Q33635039-5C42443C-3EAC-4B8A-BA9F-8B02C26291C0

P31

Q33635039-5B765A35-68B2-420C-BF57-6B77126906F5

P356

Q33635039-E8C6EFC4-182F-4F2E-A761-EEBD6562045B

P478

Q33635039-314F357E-4CC7-49FC-97E6-FA3100787C75

P577

Q33635039-A8F7CA51-980E-4E01-8E9E-BFFC7CFB32C2

P698

Q33635039-AD355890-30A1-4ED4-97EA-E789F6278037

P932

Q33635039-A4629485-5F54-429E-92D4-76C6AF3054F4

P356

P1433

Therapeutics and Clinical Risk Management

P1476

Profile of etravirine for the treatment of HIV infection

@en

P2093

Alice Tseng

http://www.w3.org/2001/XMLSchema#string

Rodger D Macarthur

http://www.w3.org/2001/XMLSchema#string

P2860

A pharmacokinetic study of etravirine (TMC125) co-administered with ranitidine and omeprazole in HIV-negative volunteers

Minimal pharmacokinetic interaction between the human immunodeficiency virus nonnucleoside reverse transcriptase inhibitor etravirine and the integrase inhibitor raltegravir in healthy subjects.

Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel.

TMC125, a novel next-generation nonnucleoside reverse transcriptase inhibitor active against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus type 1.

Sustained HIV RNA suppression after switching from enfuvirtide to etravirine in the early access programme.

Raltegravir, etravirine and r-darunavir combination in adolescents with multidrug-resistant virus.

High rate of virologic suppression with raltegravir plus etravirine and darunavir/ritonavir among treatment-experienced patients infected with multidrug-resistant HIV: results of the ANRS 139 TRIO trial.

Efficacy and safety of etravirine in treatment-experienced, HIV-1 patients: pooled 48 week analysis of two randomized, controlled trials.

A comparison of HIV-1 drug susceptibility as provided by conventional phenotyping and by a phenotype prediction tool based on viral genotype.

Raltegravir, etravirine, and ritonavir-boosted darunavir: a safe and successful rescue regimen for multidrug-resistant HIV-1 infection.

P304

49-58

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2147/TCRM.S3128

http://www.w3.org/2001/XMLSchema#string

P478

6

http://www.w3.org/2001/XMLSchema#string

P577

2010-02-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20169036

http://www.w3.org/2001/XMLSchema#string

P932

2817788

http://www.w3.org/2001/XMLSchema#string